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bstract
Combined hepatocellular-cholangiocarcinoma is a rare but unique primary hepatic tumor with characteristic histology and tumor biology.
ecent development in genetics and molecular biology support the fact that combined hepatocellular-cholangiocarcinoma is closely linked with
holangiocarcinoma, rather than hepatocellular carcinoma.
Combined hepatocellular cholangiocarcinoma tends to present with an more aggressive behavior and a poorer prognosis than either hepatocellular
arcinoma or cholangiocarcinoma. An accurate preoperative diagnosis and aggressive treatment planning can play crucial roles in appropriate patient
anagement.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
icenses/by-nc-nd/3.0/).
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4.  Introduction
Combined hepatocellular-cholangiocarcinoma (cHCC-CC)
s a rare variant of primary hepatic cancer, with the reported
ncidence of this tumor varying between 0.4 and 4.7% [1–4].
owever, as histopathological confirmation is not necessary to
iagnose HCCs and vast majority of HCCs are diagnosed based
n imaging findings, the projected incidences of cHCC-CC may
ot be accurate.
The first comprehensive review and histopathologic classifi-
ation of cHCC-CC was given by Allen and Lisa in 1949 [1].
According to the World Health Organization (WHO), a
efinitive histopathological diagnosis of cHCC-CC requires
emonstration of unequivocally differentiated hepatocellular
nd biliary components in the tumor [5].
The natural history of this rare cancer remains unclear. Most
f the initial studies originated on the Asian subcontinent and
upported the idea that this rare entity of hepatic malignancy
s intimately related to hepatocellular carcinoma (HCC) and
ollows identical demographics and clinical presentation [6,7].
owever, certain scattered Western studies reinforced a pro-
le similar to cholangiocarcinoma [2,4]. More recent studies
ave exhibited a genetic, demographic and clinical profile that
s intermediate between CC and HCC [8].
Regardless of its ambiguous natural history, cHCC-CC tends
o present with a more aggressive behavior and poorer progno-
is than either HCC or CC [7,9]. This aggressive behavior of
he tumor can be attributed to propensities for vascular invasion,
elatively large tumor size, regional adenopathy and satellite
esions [2,6,10]. Due to a dismal long-term prognosis, an accu-
ate preoperative diagnosis and aggressive treatment planning
an play crucial roles in appropriate patient management.
We present a contemporary and comprehensive review of this
are but unique primary hepatic malignancy with an overview
f its natural history, recent advances in genetics and molecular
iology, histopathogenesis, imaging and diagnosis.
.  Epidemiology  and  clinical  features
A clear benchmark for the demographic and clinical profile
f this rare cancer remains elusive.
Most of the initial studies advocated numerous resemblances
etween cHCC-CC and HCC. These studies suggested a similar
atient profile including a strong male predominance, elevated
erum AFP, and associated underlying cirrhosis (40%) and/or
epatitis (70%) and regarded cHCC-CC as an HCC variant [2];
ost of these studies were from Asia [7,11–17].
Later, a few Western studies instead demonstrated demo-
raphic, clinical, and pathologic features similar to that of CC,
d
hncluding absence of HCC risk factors such as cirrhosis or hep-
titis, no gender predominance, and normal serum AFP [2,4,18].
he situation became even more ambiguous when some of the
ore recent Western studies demonstrated clinical and demo-
raphic features intermediate to that of HCC and CC. Recent
esearch has supported this fact: Risk factors for HCC were
ound in 10% of CC, 66% of cHCC-CC, and 83% of HCC, and
irrhosis was noted in 0% of CC, 20% of cHCC-CC, and 54%
f HCC patients. Strong male predominance (14:1) remained a
on-variable feature [8].
These variations in patient profile are difficult to explain,
ut may relate not only to histogenetic variation based on race,
ut also to disparate environmental carcinogenic factors, given
ifferent geographic locales.
.  Classiﬁcation
cHCC-CC can be classified pathologically as well as geneti-
ally.
The earliest comprehensive pathologic classification was
iven by Allen and Lisa in 1949 and consisted of 3 subtypes: type
, characterized by synchronous, separate and autonomous epi-
enters of HCC and CC in one liver; type B, comprised of closely
dmixing distinguished foci of HCC and CC; and type C, con-
isting of truly combined HCC and CC components originating
rom the same tumor [1].
In the 1980s, Goodman proposed another classification
ncompassing three subtypes: (a) type 1 (or collision tumor):
ynchronous or metachronous occurrence of distinct epicenters
f HCC and CC in the same liver, which collide each other;
b) type 2 (or transitional tumor): intimate intermingling of two
omponents with actual transition of HCC elements to CC ele-
ents in the same tumor; and (c) type 3 (or fibrolamellar tumor):
imilar to a fibrolamellar HCC, but with mucin-producing pseu-
oglands [4].
Lisa and Allen’s type C is the equivalent of Goodman’s type
 (transitional tumor), and both of these types most closely
t the current WHO criteria, which define cHCC-CC as inti-
ately mixed elements of fully differentiated hepatocellular
arcinoma (HCC) and cholangiocarcinoma (CC) components
ith identification of transitional or intermediate areas [5]. To
void unnecessary confusion, only WHO classification should
e followed.
.  ImmunohistopathologyAs histopathology remains the only avenue for definitive
iagnosis, the biopsy sample must show clear evidence of both
epatocellular and biliary differentiation of monoclonal origin,
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ith the respective tumor cells intermingling intimately [5].
igns of HCC differentiation would include bile production
nd bile canaliculi as well as a pseudoglandular or trabecu-
ar growth pattern, whereas signs of CC differentiation would
nclude mucin-producing biliary epithelium forming true glan-
ular structures surrounded by desmoplastic stroma (Fig. 1d
nd e and Fig. 2h) [19]. Moreover, the tumor must also sat-
sfy the typical immunohistochemical stains of both HCC and
C and should always be in the differential diagnosis if there
re immunophenotypical features of both CC and HCC within
he lesion [20]. Exclusion of collision tumor, e.g., separate foci
f CC and HCC without intimate mixing, is obligatory, as this
ould not be considered a true cHCC-CC.
Biliary cell stains include mucin, CK7, and CK19, while hep-
tocellular stains comprise polyclonal CEA, Hep Par 1, and
D10 (Fig. 2g). The newly introduced hepatocellular marker
lypican-3 is highly sensitive and specific for identification of
CC component and only weakly reactive with CC [3,21].
Proper sampling targeting the transitional areas is vital for
ccurate immunohistological diagnosis.
However, despite accurate sampling, accurate pre-operative
iagnosis might be thwarted by certain pitfalls in immuno-
istochemical analysis [3]. For example, one can misinterpret
he pseudoglandular structure of HCC for the true glandular
tructures of CC; here, mucin staining would be useful [3].
L
c
g
ig. 1. 59-Year-old man with chronic hepatitis B. (a) Axial CT (arterial phase): hypode
b) Venous phase: foci of peripheral enhancement in the hypodense mass (arrow). (c)
hase (asterisk) surrounded by hypodense rim (large arrow). Washout is evident in th
mages at 4× and 10×  magnifications showing malignant cells of hepatocellular carci
figure d, box). The diagnosis was consistent with CC dominant cHCC-CC. Radiology Open 1 (2014) 40–48
dditionally, CK7 and CK19 may not be entirely specific for
C, as it can be expressed in HCC as well [22]. Finally,
mmunohistochemical staining is not useful in differentiating
he inflammatory biliary ductal reactivity usually present with
CC from the malignant biliary epithelium of true CC. One
ifferential factor to avoid this hazard would be that a true CC
omponent would demonstrate desmoplastic stroma rather than
he inflammatory cells of ductal reactivity [3].
.  Genetics  and  molecular  analysis
Classically HCC demonstrates certain peculiar genetic alter-
tions including loss of heterozygosity (LOH) at chromosomes
p, 17p, 4q, 1p, 16q, 13q, 6q, 16p, and 9p. Additionally, inac-
ivation of tumor suppressor genes like TP53, and activation
f oncogenes like CTNNB1/-catenin (and the Wnt pathway)
as been implicated in the etiopathogenesis of HCC. On the
ther hand, a microsatellite instability (MSI-H) phenotype, TP53
nd KRAS2 mutations have been described in CC. However,
parse information about the genetics and molecular biology of
HCC-CC is available in the literature.Genome-wide typing has demonstrated higher incidences of
OH at chromosomes 3p and 14q in cHCC-CC and CC and
an be taken as specific to these tumors [8]. Tumor suppressor
ene RASSF1 (part of the ras signaling pathway) is located in the
nse mass is seen in the right hepatic lobe (circle). Note incidental cholelithiasis.
 Equilibrium phase: the mass demonstrates central enhancement in the delayed
e previously seen peripheral enhancing foci (small arrow). (d and e) H&E stain
noma (figure d, asterisk) seen alongside malignant cells of cholangiocarcinoma
S. Maximin et al. / European Journal of Radiology Open 1 (2014) 40–48 43
Fig. 2. 42-Year-old-Vietnamese woman with history of hepatitis. (a) Axial T1w in-phase image shows hypointense mass in right hepatic lobe (arrow). (b) Axial T1w
opposed-phase image shows no signal drop, which rules out presence of (microscopic) fat (therefore adenoma or well differentiated HCC). (c) Axial T2w image
shows peripheral rind of intermediate signal intensity (arrow) with central hypointensity (asterisk). Scattered foci of hyperintensity centrally (small arrow). (d) Arterial
phase shows peripheral enhancement of the mass (arrow) with minimally enhancing central component (asterisk). (e) Venous phase demonstrates washout in the
periphery (arrow) and progressively enhancing central component which corresponds to fibrosis within the CC component at subsequent histopathology (asterisk).
(f) Equilibrium phase shows persistent central enhancement (asterisk). (g) H&E stain images at 4× magnifications showing mixed components. (h) CD10 antibody
staining protocol for immunohistochemistry. (i) Glypican-3 staining highlighting the HCC component.
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egion of 3p LOH [23]. However, no definitive tumor suppressor
ene has been found in the region of 14q LOH. Potentially, LOH
t 3p and 14q could also be exploited to discriminate between
epatocellular and biliary differentiation of the tumor.
Mutation of tumor suppressor gene TP53 cannot be correlated
ith tumor differentiation in primary hepatic tumors, as it is
een in 11% of CC, 27% of cHCC-CC, and 26% of HCC [8].
owever, detection of the activation of the CTNNB1/-catenin
ncogene may be helpful, given that this mutation is found in
0% of HCC but is not found in cHCC-CC or CC [8,24].
It is apparent that analysis of certain genetic signatures may
ot only help differentiate these tumors, but will also promote
urther genetic analysis to better understand genetic variations
nd ultimately the disparities in clinical presentation and prog-
osis. Extensive studies are needed to further explore the genetic
lterations specific to cHCC-CC.
.  Histogenesis
While the cell of origin of this cancer remains controver-
ial, genetic and molecular analysis have been instrumental in
urthering theories of histogenesis. Given the known bidirec-
ional differentiation potential of both hepatocytes and biliary
pithelium in rat models and humans, it has been postulated
hat the cell of origin is either a dedifferentiated CC or HCC
r, more likely, a transitional or intermediate hepatic progenitor
ell [4,25].
Using microdissection and DNA extraction, Fujii et al.
bserved 3 tumor types based on LOH patterns: type 1, a
ollision tumor of two truly independent clones; type 2, a homo-
eneous bidirectional (hepatic and biliary) monoclone; and type
, a bidirectional monoclone, but with histologic diversity as a
esult of subclones, with probable overlap of types 2 and 3. This
emonstration of common allelic losses in each element of the
esion strongly supports the hypothesis that these cancers are of
onoclonal origin with bidirectional phenotypic differentiation
26].
.  Imaging
Given the poorer prognosis of cHCC-CC compared to HCC
r CC, accurate pretreatment diagnosis is critical because it can
lter management decisions.
Imaging features of cHCC-CC are scarcely described in
he literature. Awareness of characteristic imaging features of
HCC-CC may enable a radiologist to identify or screen these
umors pre-operatively and perform image-guided biopsies.
.1.  Ultrasound
The sonographic appearance of cHCC-CC is non-specific;
t may demonstrate a target appearance consisting of a round
ypoechoic mass with a central hyperechoic focus or a heteroge-
eous hypoechoic mass. Heterogeneity likely reflects histologic
iversity [27]. However, ultrasound could be a useful tool to get
 targeted image-guided sample from a suspicious mass.
s
b
(
i Radiology Open 1 (2014) 40–48
.2.  CT
On non-contrast computed tomography (CT), cHCC-CC
emonstrates a non-specific appearance and appears hypodense
r isodense to liver parenchyma.
On contrast-enhanced CT a variable pattern of enhancement
as been described. The pattern of enhancement is governed
ot only by the proportion and distribution of the CC vs. HCC
omponent, but also by the gamut of histological patterns of CC.
ifferent histologic subtypes of CC have been shown to have
arying enhancement patterns. The medullary type demonstrates
arly phase enhancement, whereas the scirrhous type shows late-
hase enhancement. On the other hand, the HCC component
hows early hyper-enhancement and delayed washout.
Different researchers have made efforts to classify cHCC-CC
ccording to their enhancement patterns. Aoki et al. described
wo types of CT enhancement patterns [13]: (1) Type A: This
ubtype demonstrates a peripheral enhancement in the early
hase with central hyperenhancement and peripheral washout
n the delayed phase. This pattern can be explained by concen-
ric zones of HCC peripherally and CC centrally, with associated
ransitional zones in between; (2) Type B: This subtype closely
ollows the enhancement demonstrated by classical HCC (dif-
use early hyperenhancement and diffuse washout on delayed
hase).
Sanada et al. identified three enhancement patterns [28]: (1)
ype I: Early hyperenhancement followed by washout in the
elayed phase; (2) Type II: Peripheral enhancement in both
he early and delayed phases; and (3) Type III: Two distinc-
ive enhancement patterns in the same tumor, one following
he typical HCC pattern (early enhancement with delayed-phase
ashout) and the second imitating CC (delayed enhancement on
ate imaging).
It is apparent from the description that Aoki’s type B and
anada’s type 1 follow the typical HCC pattern and would most
ertainly result in a preoperative imaging diagnosis of HCC
ather than cHCC-CC or CC [28]. Histologically, these tumors
re HCC-predominant lesions.
Sanada’s type III, similar to Aoki’s type A, is the most sugges-
ive of cHCC-CC on imaging. This is a combination of typical
maging features of both HCC and CC, and manifestation of this
attern on imaging should immediately raise suspicion, regard-
ess of the clinical presentation or serum tumor markers [28].
istologically, these tumors are comprised of both HCC and
C components (Fig. 1a–e).
Sanada’s type II pattern remains atypical and can be explained
y the presence of central fibrotic or necrotic components
ttached to a peripheral cHCC-CC component.
.3.  MRI
MRI features of cHCC-CC have not been described exten-
ively. To the best of our knowledge, less than ten studies have
een published at the time of writing this article [29–34].
The cHCC-CC may appear hypointense on T1w images
Fig. 2a and b). On T2w images, they usually demonstrate
ntermediate to high signal intensity with or without central
nal of
h
c
l
C
p
w
m
e
m
a
h
h
i
i
i
a
t
h
a
w
c
s
r
p
M
a
t
e
w
a
H
8
m
t
D
m
e
t
o
H
a
t
A
d
d
s
a
p
c
e
s
u
d
F
h
h
e
t
i
w
F
d
e
d
c
a
e
h
t
t
a
T
D
U
T
T
A
E
G
M
CS. Maximin et al. / European Jour
ypointense focus, which corresponds to a central CC or fibrotic
omponent (Fig. 2c).
On dynamic imaging, the enhancement patterns usually fol-
ow patterns similar to those described by Aoki and Sanada on
T imaging (Fig. 2d and f) [33,35]. More recently, de Cam-
os et al. have also described features of MR imaging that
ere variations on Sanada’s descriptions: early ring enhance-
ent with progressive enhancement centrally, or heterogeneous
arly enhancement with partial washout [34].
MR imaging with a hepatocellular agent like gadoxetic acid
ay also be useful to differentiate cHCC-CC and CC. Gadoxetic
cid has both perfusion and hepatocyte-selective features and is
ighly liver-specific, with about 50% of the dose taken up by
epatocytes as early as one minute after injection. Hepatobil-
ary phase imaging can then be done 10–20 min after injection
n conjunction with dynamic phase imaging earlier. Character-
zation of lesions on routine MR with standard extracellular
gents is based on precontrast signal characteristics as well as
he postcontrast perfusion pattern; dual function contrast agents,
owever, allow characterization with all of these features as well
s cellular differentiation because of the hepatocyte selectivity,
hich has typically required histopathology. In the setting of
HCC-CC, the various appearances of this lesion may not neces-
arily relate to hepatocyte selectivity, however, but regardless can
esult in specific patterns which are suggestive [35]. For exam-
le, Hwang retrospectively evaluated gadoxetic acid-enhanced
R images of a pathologically proven series of 20 cases of CC
nd 20 cases of cHCC-CC to assess for imaging discrimina-
ors [36]. Their data suggested that a lobular shape, weak rim
nhancement, and a complete target appearance favored CC,
hile an irregular shape, strong peripheral enhancement and
bsence of the target sign favored cHCC-CC, particularly the
CC predominant type.
.  Differential  diagnosis
Classical imaging pattern of cHCC-CC may closely resemble
etastasis [34]. Both hypervascular and hypovascular metas-ases share this pattern, particularly on MR imaging [37].
iagnostic consideration of metastasis should be considered
ore likely in a patient without underlying liver disease
ven without history of known primary malignancy, given
9
t
able 1
ifferential diagnosis of cHCC-CC.
cHCC-CC 
nderlying liver disease Common 
1w Hypointense 
2w Intermediate SI +/− central hypointensit
rterial phase Varies according to dominant histologica
but classically contains area of hypervasc
quilibrium phase Area of contrast retention 
adoxetic acid (hepatobiliary phase) Partial or complete target appearance 
ultiplicity – 
entral necrosis –  Radiology Open 1 (2014) 40–48 45
he rarity of cHCC-CC [34,37]. Other discriminators in favor
f metastases include multiple lesions or central necrosis.
epatocyte-selective imaging on MR with gadoxetic acid will
lso differentiate a metastasis from cHCC-CC, with the metas-
asis typically non-enhancing on the hepatobiliary phase [35].
 quick reference of cHCC-CC versus metastasis has been
epicted in Table 1. In a patient with chronic underlying liver
isease, metastases are less likely, so this pattern would more
trongly suggest cHCC-CC. However, very aggressive HCC has
lso been shown to have this particular ring-like enhancement
attern and thus should also be considered [38].
Other enhancement patterns of cHCC-CC are much less spe-
ific. A histopathologically HCC-predominant cHCC-CC with
arly uniform hyperenhancement and delayed washout will rea-
onably be described preoperatively as an HCC in a liver with
nderlying chronic disease, while in a liver without underlying
isease, the differential diagnosis would include HCC, adenoma,
NH, and hypervascular metastasis [34,39]. Willekens et al.
ave reported one case of a pathologically proven cHCC-CC that
ad the typical appearance of FNH on MRI imaging, including
arly phase enhancement and delayed enhancement of a cen-
ral scar, which can mimic cHCC-CC [33]. One discriminator
s the T1w appearance, as cHCC-CC can appear hypointense,
hile FNH will be iso- or hyperintense. Additionally, given that
NH is hepatocellular in origin, gadoxetic acid imaging with MR
uring the hepatocyte-selective phase will demonstrate typical
nhancement of the entire lesion, unlike cHCC-CC [35,36].
Histopathologically CC-predominant cHCC-CC lesions that
emonstrate minimal early peripheral enhancement and strong
entral enhancement on delayed imaging will likely be described
s CC at CT or MR imaging. While it is very difficult to differ-
ntiate these two cancers, a complete target appearance on the
epatobiliary phase of gadoxetic acid imaging is more sugges-
ive of CC than CC-predominant cHCC-CC [36].
Serum tumor marker levels should always be correlated with
he imaging appearance to increase the accuracy of the preoper-
tive differential diagnosis [34]..  Treatment  and  prognosis
The prognosis of cHCC-CC is dismal, even with resec-
ion. Various prognostic factors described in different studies
Metastasis
Unusual
Usually hypointense
y Moderate-marked hyperintense
l component
ularity
Variable according to the primary but ring-like
hypervascularity can be seen
May demonstrate fill in or become hypointense to
parenchyma
No contrast retention
Often
May present
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Fig. 3. Algorithmic approach to elevated tumor markers and enhancement pat-
tern on imaging.
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ike tumor size, presence of satellite nodules and lymph nodal
nvolvement are not definitive. Early reports demonstrated that
n cHCC-CC, tumor size (median 8.8 cm), presence of satellite
umors (29%), and incidence of vascular invasion and lymph
ode involvement were not significantly different statistically
ompared to CC or HCC [2]. Other studies reported significantly
ncreased lymph node involvement and vascular invasion as well
s poorer overall survival when compared to HCC, although
hese were all similar to CC [6,10]. Additionally, multifocal
isease and decreased capsular formation in cHCC-CC were
egarded as signs of more aggressive behavior compared to HCC
14,40]. Early reports stated that tumor stage, size, vascular inva-
ion, and multifocality were poor prognostic indicators [14,41],
hile a more recent study has indicated that an elevated CA
9-9 level was the only statistically significant indicator of poor
urvival [40].
While resection with node dissection is the only curative
ption [40], contemporary evidence is that prognosis after resec-
ion is worse than CC or HCC [7,9]. One such study assessed
edian time-to-recurrence (TTR) and overall survival (OS) after
urative resection in cHCC-CC, CC, and HCC; median TTR and
S for cHCC-CC were 5.4 and 18 months, both significantly
horter than CC or HCC [9]. Additionally, 5-year survival rates
ave been reported at 23–24%, lower than either CC or HCC
20,40].
Despite the poor prognosis regardless of current treatment
odalities, it must be emphasized that the correct diagno-
is is still necessary. Treating cHCC-CC as with the typical
anagement for either CC or HCC will not allow further stud-
es exploring more comprehensive multimodality treatments,
ncluding extended hepatectomy, regional node dissection and
djuvant therapy. Regional treatments such as transarterial
hemoembolization (TACE) are theoretically not an ideal treat-
ent option because the fibrotic CC component of cHCC-CC
ill have relatively poor uptake of therapeutic agents, but local-
zed treatments such as TACE and RFA have been attempted
s part of a multimodality approach for recurrent disease
40,42]. Liver transplant or radioembolization should also be
ssessed, as their role currently remains uncertain in this
isease [16,43].
0.  Making  the  pre-operative  diagnosis
While the complex nature of this cancer makes specific
maging diagnosis difficult, the radiologist should suggest this
iagnosis and prompt an expanded preoperative image-guided
iopsy by assessing the imaging findings in conjunction with
erum tumor markers [11,34,44,45]. The expanded biopsy
hould be more comprehensive than a typical biopsy, and try
o include some of the transitional areas noted on the imaging
tudy.The combination of imaging features and tumor markers (CA
9-9 and AFP) could be useful in screening cHCC-CC and
rompting for an image-guided biopsy (Fig. 3). The diagno-
is of cHCC-CC should be strongly considered in the following
ircumstances (Fig. 4):
d
p
c
f
gFig. 4. Making pre-operative diagnosis of cHCC-CC.
. If the lesion demonstrates imaging features of both CC and
HCC, regardless of marker levels.
. If both AFP and CA 19-9 are elevated, regardless of imaging
appearance.
. If the imaging appearance contradicts the tumor marker, e.g.,
typical HCC enhancement pattern with elevated CA 19-9 or
conventional CC enhancement pattern with abnormal AFP.
ost-biopsy, the diagnosis is made based on immunohistopatho-
ogical features.
1.  Conclusion
Because of its rare occurrence, gamut of demographic and
linical profiles, ambiguous imaging features, and inconsistent
pplication of histopathologic criteria, preoperative diagnosis of
HCC-CC remains challenging. Nevertheless, the pre-operative
iagnosis remains critical due to its aggressive nature and poor
rognosis in comparison to HCC and CC. A combination of
ertain imaging features and levels of serum tumor markers
acilitates a high level of suspicion, prompting a carefully tar-
eted (sampling some of the transitional areas noted on the
nal of
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maging study) extended biopsy. The final diagnosis of cHCC-
C is based on immunohistopathology, special stains, and
enetic analysis and allows appropriate and aggressive treatment
lanning. Continued investigation and research are required to
stablish the roles of both advanced imaging and molecular anal-
sis in the diagnosis, classification, and treatment of cHCC-CC.
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